To successfully defend legal challenges against
compensation committee decisions, biopharmaceutical companies must make greater efforts to obtain the necessary approvals from stockholders.
Healthcare industry partners Doreen Lilienfeld
, Brian Polovoy
and Mark Kessel
co-authored a letter to the editor on this subject that was published in Nature Biotechnology
. According to the authors, biopharmaceutical companies will ignore the Delaware director compensation cases at their own peril.
View full article, Delaware Director Compensation Cases